BPC-157 Reference

Educational, not medical advice reference for BPC-157: Recovery; regulatory status, evidence posture, source review, and schedule notes. Also kn…

Plain English

What it is
BPC-157 is a lab-made peptide, which is a short chain of protein building blocks. It is sold mostly as a research chemical, taken as a shot under the skin or by mouth, and it is not an approved medicine for people.
What people use it for
In peptide and fitness communities, people reach for it hoping to speed up healing of injuries, tendons, ligaments, and gut problems, and some pair it with another peptide called TB-500. These uses come from community word of mouth, not from approved medical directions.
What the science shows
Almost all of the encouraging results come from animal studies, mostly in rodents. Human testing is very small (only a few early pilot studies), so there is no solid proof yet that it works or is safe in people.
The catch
It is not an approved medicine, and there is no legal pathway to have it made by a compounding pharmacy. The World Anti-Doping Agency bans it for athletes as a non-approved substance. One open safety question is that it spurs the growth of new blood vessels, and because tumors also feed on new blood vessels, a theoretical cancer concern has not been ruled out in people.

Reference summary

Published literature is dominated by preclinical rodent injury-healing work spanning tendon, ligament, muscle, gastrointestinal mucosa, vascular, and central-nervous-system models. Mechanistic work points to VEGFR2 activation and the Akt-eNOS nitric oxide pathway driving angiogenesis, fibroblast migration, and neuromuscular stabilization, particularly in poorly vascularized tissues such as tendons and myotendinous junctions. Direct human evidence remains extremely limited. The original Pliva-sponsored Phase 2 program of PL 14736 enema for mild-to-moderate ulcerative colitis was completed but never published in a peer-reviewed journal, and only a small number of pilot reports exist in humans. A 2025 narrative review in Current Reviews in Musculoskeletal Medicine concluded that BPC-157 should still be considered investigational and used with caution until well-designed human trials are conducted.

Regulatory and posture

Categories
Recovery
Aliases
BPC 157, Body Protection Compound-157, Pentadecapeptide BPC-157, Stable gastric pentadecapeptide BPC 157, PL 14736, PL-10, PLD-116
Evidence posture
preclinical - Mostly animal data. Pliva Phase 2 ulcerative-colitis program (PL 14736) was abandoned and never published; only a handful of small human pilot reports exist.
Regulatory status
No FDA-approved drug label for human use. On September 29, 2023, FDA placed BPC-157 (acetate and arginate salt forms) in Category 2 of the 503A interim bulk drug substances list, meaning FDA identified significant safety concerns. BPC-157 now sits in FDA's table of bulk drug substances previously in Category 2 whose nominations were withdrawn by the nominators, rather than in the current Category 2 table. Either way it is not on the 503A Bulks List and is not permitted for use in section 503A pharmacy compounding. On April 16, 2026, FDA published a Federal Register notice (docket FDA-2025-N-6895) scheduling a Pharmacy Compounding Advisory Committee meeting for July 23-24, 2026 to consider BPC-157 (free base and acetate), along with TB-500, KPV, and MOTS-c, for inclusion on the 503A Bulks List (FDA-evaluated use: ulcerative colitis). At that meeting the committee narrowly recommended inclusion, against FDA's own reviewers, but the recommendation does not bind FDA and BPC-157 remains not permitted for 503A compounding unless and until FDA completes rulemaking. Prohibited at all times (in-competition and out-of-competition) under WADA S0 non-approved substances. No therapeutic use exemption is available because BPC-157 is not approved for human therapeutic use in any country.
Content review status
research reference

Selected public sources

Related tools

For research and educational purposes only. Not medical advice.